Eupraxia Pharmaceuticals Inc (EPRX) - Net Assets

Latest as of September 2025: CA$123.06 Million CAD ≈ $89.02 Million USD

Based on the latest financial reports, Eupraxia Pharmaceuticals Inc (EPRX) has net assets worth CA$123.06 Million CAD (≈ $89.02 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$128.50 Million ≈ $92.95 Million USD) and total liabilities (CA$5.43 Million ≈ $3.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check EPRX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CA$123.06 Million
% of Total Assets	95.77%
Annual Growth Rate	36.79%
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	1710.28

Eupraxia Pharmaceuticals Inc - Net Assets Trend (2017–2024)

This chart illustrates how Eupraxia Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore EPRX current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Eupraxia Pharmaceuticals Inc (2017–2024)

The table below shows the annual net assets of Eupraxia Pharmaceuticals Inc from 2017 to 2024. For live valuation and market cap data, see EPRX stock market capitalisation.

Year	Net Assets	Change
2024-12-31	CA$45.77 Million ≈ $33.11 Million	+3790.21%
2023-12-31	CA$1.18 Million ≈ $851.15K	-89.65%
2022-12-31	CA$11.36 Million ≈ $8.22 Million	-41.88%
2021-12-31	CA$19.55 Million ≈ $14.14 Million	+190.26%
2020-12-31	CA$-21.66 Million ≈ $-15.67 Million	-19.49%
2019-12-31	CA$-18.13 Million ≈ $-13.12 Million	-58.55%
2018-12-31	CA$-11.44 Million ≈ $-8.27 Million	-323.94%
2017-12-31	CA$5.11 Million ≈ $3.69 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Eupraxia Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 11089506200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	CA$116.36 Million	348.33%
Other Comprehensive Income	CA$-5.98 Million	-17.91%
Other Components	CA$54.03 Million	161.75%
Total Equity	CA$33.40 Million	100.00%

Eupraxia Pharmaceuticals Inc Competitors by Market Cap

The table below lists competitors of Eupraxia Pharmaceuticals Inc ranked by their market capitalization.

Company	Market Cap
JSL S.A SA:JSLG3	$394.04 Million
Shanghai Rychen Technologies Co. Ltd. A SHE:301273	$394.07 Million
Lootom Telcovideo Network Wuxi Co Ltd SHE:300555	$394.22 Million
Chieftek Precision Co Ltd TW:1597	$394.51 Million
BNY Mellon Strategic Municipals Inc NYSE:LEO	$393.68 Million
Acacia Research Corporation NASDAQ:ACTG	$393.56 Million
Ambac Financial Group Inc NYSE:AMBC	$393.43 Million
Xinjiang Tianshun Supply Chain Co Ltd SHE:002800	$393.23 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Eupraxia Pharmaceuticals Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 2,216,207 to 33,404,803, a change of 31,188,596 (1407.3%).
Net loss of 34,937,494 reduced equity.
Share repurchases of 54,921,670 reduced equity.
New share issuances of 54,558,610 increased equity.
Other comprehensive income decreased equity by 2,397,610.
Other factors increased equity by 68,886,760.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CA$-34.94 Million	-104.59%
Share Repurchases	CA$54.92 Million	-164.41%
Share Issuances	CA$54.56 Million	+163.33%
Other Comprehensive Income	CA$-2.40 Million	-7.18%
Other Changes	CA$68.89 Million	+206.22%
Total Change	CA$-	1407.30%

Book Value vs Market Value Analysis

This analysis compares Eupraxia Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 10.92x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 23.13x to 10.92x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	CA$0.46	CA$10.75	x
2018-12-31	CA$-0.86	CA$10.75	x
2019-12-31	CA$-1.38	CA$10.75	x
2020-12-31	CA$-1.65	CA$10.75	x
2021-12-31	CA$1.43	CA$10.75	x
2022-12-31	CA$0.67	CA$10.75	x
2023-12-31	CA$0.09	CA$10.75	x
2024-12-31	CA$0.98	CA$10.75	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Eupraxia Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -104.59%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.50x
Recent ROE (-104.59%) is above the historical average (-269.71%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2017	-72.22%	0.00%	0.00x	0.98x	CA$-4.92 Million
2018	0.00%	0.00%	0.00x	0.00x	CA$-12.13 Million
2019	0.00%	0.00%	0.00x	0.00x	CA$-5.41 Million
2020	0.00%	0.00%	0.00x	0.00x	CA$-1.88 Million
2021	-112.77%	0.00%	0.00x	1.53x	CA$-25.03 Million
2022	-180.93%	0.00%	0.00x	2.01x	CA$-24.54 Million
2023	-1687.19%	0.00%	0.00x	12.06x	CA$-37.61 Million
2024	-104.59%	0.00%	0.00x	1.50x	CA$-38.28 Million

Industry Comparison

This section compares Eupraxia Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $26,768,748
Average return on equity (ROE) among peers: -68.27%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Eupraxia Pharmaceuticals Inc (EPRX)	CA$123.06 Million	-72.22%	0.04x	$393.86 Million
Appili Therapeutics Inc (APLI)	$-13.40 Million	0.00%	0.00x	$1.86 Million
Aptose Biosciences Inc (APS)	$7.33 Million	-189.11%	0.18x	$4.36 Million
Arch Biopartners Inc (ARCH)	$1.06 Million	-79.15%	0.19x	$20.88 Million
Biomind Labs Inc (BMND)	$-1.30 Million	0.00%	0.00x	$6.98 Million
Cybin Inc (CYBN)	$237.20 Million	-47.70%	0.09x	$301.37 Million
Devonian Health Group Inc (GSD)	$14.25 Million	-32.28%	0.35x	$20.01 Million
Helix BioPharma Corp. (HBP)	$-1.39 Million	0.00%	0.00x	$116.58 Million
Hemostemix Inc (HEM)	$-6.77 Million	0.00%	0.00x	$8.18 Million
Universal Ibogaine Inc (IBO)	$3.94 Million	-266.20%	0.60x	$1.13 Million

About Eupraxia Pharmaceuticals Inc

TO:EPRX Canada Biotechnology

Market Cap

$393.86 Million

CA$544.47 Million CAD

Market Cap Rank

#13760 Global

#396 in Canada

Share Price

CA$10.75

Change (1 day)

+0.94%

52-Week Range

CA$5.16 - CA$12.50

All Time High

CA$12.50